The rating assignment is based on Dana-Farber’s strong working partnerships with other academic institutions and prominent market position in the field of cancer research and treatment.
The outlook is stable, reflecting Moody’s Investors Service’s expectation that Dana-Farber will continue to translate its leading reputation in cancer research into strong revenue and resource growth.
Moody’s Investors Service has also affirmed the “A1” ratings on Dana-Farber’s $233 million of outstanding revenue bonds.
More articles on healthcare finance:
Craneware, OhioHealth to present on pharmacy revenue integrity HFMA’s Annual National Institute
NJ owes counties $37M in Medicaid repayments
Moody’s affirms Flagler Hospital’s ‘A3’ rating
